Authorized purpose: Adjunctive brain MRI morphometry and lesion-quantification support for qualified healthcare professionals, including segmented overlays, volumetric measurements, normative percentiles and longitudinal comparison.
Clinical role
Automated quantitative and visualization aid; results are reviewed by a qualified medical professional and do not replace clinical judgment.
Images and patients
MRI · Brain
Key limitation
Keep in mind: The product is adjunctive and requires professional review. Automated quality control and protocol checks do not remove the need to verify image quality, acquisition compatibility and clinical context.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Adjunctive brain MRI morphometry and lesion-quantification support for qualified healthcare professionals, including segmented overlays, volumetric measurements, normative percentiles and longitudinal comparison.
Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Brain Input: DICOM brain MRI with specified 3D T1 and T2 FLAIR acquisitions and protocols; supported scanners and acquisition requirements define the cleared processing scope.
Who uses it?Intended users: Radiologists, neurologists and other qualified healthcare professionals interpreting brain MRI.
What does the software produce?Output: Segmented color overlays, labels and volumes, age- and sex-matched reference percentiles, prior-study comparison, morphometric reports, and PACS/DICOM and PDF-style report outputs described in the submission.
What is its most important limitation?Key limitation: The product is adjunctive and requires professional review. Automated quality control and protocol checks do not remove the need to verify image quality, acquisition compatibility and clinical context.
Clinical takeaway. Clinical role: Adjunctive brain MRI morphometry and lesion-quantification support for qualified healthcare professionals, including segmented overlays, volumetric measurements, normative percentiles and longitudinal comparison.
Evidence takeaway. Evidence from the reviewed source record: The FDA summary reports 3D T1 accuracy and reproducibility testing across scanners and countries, with Dice thresholds above 0.80 for major subcortical structures and above 0.75 for cortical structures and mean volume differences within 5%. T2 FLAIR testing reported lesion Dice above 0.80 and mean absolute lesion-volume difference below 0.25 cc.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Adjunctive brain MRI morphometry and lesion-quantification support for qualified healthcare professionals, including segmented overlays, volumetric measurements, normative percentiles and longitudinal comparison.
DICOM brain MRI with specified 3D T1 and T2 FLAIR acquisitions and protocols; supported scanners and acquisition requirements define the cleared processing scope.
Segmented color overlays, labels and volumes, age- and sex-matched reference percentiles, prior-study comparison, morphometric reports, and PACS/DICOM and PDF-style report outputs described in the submission.
The product is adjunctive and requires professional review. Automated quality control and protocol checks do not remove the need to verify image quality, acquisition compatibility and clinical context.
The FDA summary reports 3D T1 accuracy and reproducibility testing across scanners and countries, with Dice thresholds above 0.80 for major subcortical structures and above 0.75 for cortical structures and mean volume differences within 5%. T2 FLAIR testing reported lesion Dice above 0.80 and mean absolute lesion-volume difference below 0.25 cc.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The FDA summary reports 3D T1 accuracy and reproducibility testing across scanners and countries, with Dice thresholds above 0.80 for major subcortical structures and above 0.75 for cortical structures and mean volume differences within 5%. T2 FLAIR testing reported lesion Dice above 0.80 and mean absolute lesion-volume difference below 0.25 cc.
SwiftSight-Brain 3D T1 accuracy and reproducibility
DesignAccuracy and reproducibility evaluation across scanner manufacturers, field strengths, countries and adult age decades
Population3D T1 brain MRI: 72 accuracy/reproducibility cases; scanner subsets included Philips 54, Siemens 53 and GE 37 across the reported evaluations
Scopeexact submission
Tested versionSS25-BR-CL configuration submitted in K251483
Samplen=72
IndependenceSponsor or vendor study
K251483
FDA reports Dice >0.80 for major subcortical and >0.75 for cortical structures and mean volume differences <=5%.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: DICOM brain MRI with specified 3D T1 and T2 FLAIR acquisitions and protocols; supported scanners and acquisition requirements define the cleared processing scope.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Processes DICOM brain MRI and returns segmented/quantitative results for PACS or report workflow; the exact site routing and viewer configuration require confirmation.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: Software processing service with automated QC and DICOM/PACS/report outputs; the public FDA summary does not establish the customer's hosting model.
Scope: Exact FDA submission.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Segmented color overlays, labels and volumes, age- and sex-matched reference percentiles, prior-study comparison, morphometric reports, and PACS/DICOM and PDF-style report outputs described in the submission.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Segmented color overlays, labels and volumes, age- and sex-matched reference percentiles, prior-study comparison, morphometric reports, and PACS/DICOM and PDF-style report outputs described in the submission.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Processes DICOM brain MRI and returns segmented/quantitative results for PACS or report workflow; the exact site routing and viewer configuration require confirmation.
AIRS Medical announced it obtained ISO/IEC 27001 (information security management), ISO/IEC 27017 (cloud information security), and ISO/IEC 27018 (cloud personal information protection) certifications from Bureau Veritas, scoped to the company's cloud-based services.
Vendor-wide
Checked 2026-10-27
Vendor statement (Korean-language press release on the owning domain, 2023-09-25); certificates not read. Certification scope is the company's cloud-based services. Exact-release scope is not established.
Current SwiftSight-Brain release notes describe configurable retention/auto-purge, MFA and removal of patient names from processing history or generated reports.
product family · checked 2026-09-06
These statements do not establish a formal security certification or exact K251483 contract.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-07Last searched
23Fields reviewed
12Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
Stored candidate metadata was screened; no PubMed or trial IDs were returned for this submission. This is not a full-paper review. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, vendor faq, vendor release note, stored candidate metadata, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-07 - Exact FDA submission
No public price or quote for SS25-BR-CL was reviewed.
Pricing model: Not verified - checked 2026-09-07 - Exact FDA submission
License, per-study, subscription and implementation terms were not established.
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission
Bounded web search on 2026-10-26 (query: "SwiftMR AIRS Medical reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. This records what was found, not that none exists; eligibility depends on payer, site of service and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-10-27 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-10-27 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: ANDI 2.2 processes brain MR images for atlas-assisted visualization, segmentation and volumetric quantification, presenting adjunctive DICOM-readable information for trained medical professionals; it does not predict, diagnose or interpret brain health.
Authorized purpose: Morph automatically labels, visualizes, and volumetrically quantifies segmentable brain structures from MR images and may compare measurements with reference percentile data; it is adjunctive and not the sole basis for final decisions.
Authorized purpose: Brain MRI morphometry and white matter hyperintensity quantification, including normative comparison and longitudinal change assessment for clinician review.
Authorized purpose: Adjunctive quantitative brain MRI analysis that compares patient measures with normative and longitudinal references; a physician reviews all results and makes the clinical decision.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.